NasdaqCM - Delayed Quote USD

Ekso Bionics Holdings, Inc. (EKSO)

1.2500 -0.0300 (-2.34%)
At close: April 26 at 4:00 PM EDT
1.2900 +0.04 (+3.20%)
After hours: April 26 at 5:25 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
18,279.0000
18,279.0000
12,912.0000
11,246.0000
8,882.0000
Cost of Revenue
9,200.0000
9,200.0000
6,698.0000
4,497.0000
3,812.0000
Gross Profit
9,079.0000
9,079.0000
6,214.0000
6,749.0000
5,070.0000
Operating Expense
24,191.0000
24,191.0000
21,770.0000
20,577.0000
17,928.0000
Operating Income
-15,112.0000
-15,112.0000
-15,556.0000
-13,828.0000
-12,858.0000
Net Non Operating Interest Income Expense
-302.0000
-302.0000
-156.0000
-113.0000
-139.0000
Other Income Expense
216.0000
216.0000
632.0000
4,177.0000
-2,828.0000
Pretax Income
-15,198.0000
-15,198.0000
-15,080.0000
-9,764.0000
-15,825.0000
Net Income Common Stockholders
-15,198.0000
-15,198.0000
-15,080.0000
-9,764.0000
-15,825.0000
Average Dilution Earnings
--
--
--
-1,029.0000
--
Diluted NI Available to Com Stockholders
-15,198.0000
-15,198.0000
-15,080.0000
-10,793.0000
-15,825.0000
Basic EPS
-1.10
--
-1.16
-0.80
-2.21
Diluted EPS
-1.10
--
-1.16
-0.88
-2.21
Basic Average Shares
13,867.0000
--
12,962.0000
12,193.0000
7,164.0000
Diluted Average Shares
13,867.0000
--
12,962.0000
12,269.0000
7,164.0000
Total Operating Income as Reported
-15,112.0000
-15,112.0000
-15,556.0000
-13,828.0000
-13,291.0000
Total Expenses
33,391.0000
33,391.0000
28,468.0000
25,074.0000
21,740.0000
Net Income from Continuing & Discontinued Operation
-15,198.0000
-15,198.0000
-15,080.0000
-9,764.0000
-15,825.0000
Normalized Income
-15,477.0000
-15,477.0000
-15,742.0000
-13,958.0000
-12,007.0000
Interest Expense
302.0000
302.0000
156.0000
113.0000
139.0000
Net Interest Income
-302.0000
-302.0000
-156.0000
-113.0000
-139.0000
EBIT
-14,896.0000
-14,896.0000
-14,924.0000
-9,651.0000
-15,686.0000
EBITDA
-13,198.0000
-13,198.0000
-14,037.0000
-8,628.0000
-15,066.0000
Reconciled Cost of Revenue
9,200.0000
9,200.0000
6,698.0000
4,497.0000
3,812.0000
Reconciled Depreciation
1,698.0000
1,698.0000
887.0000
1,023.0000
620.0000
Net Income from Continuing Operation Net Minority Interest
-15,198.0000
-15,198.0000
-15,080.0000
-9,764.0000
-15,825.0000
Total Unusual Items Excluding Goodwill
279.0000
279.0000
662.0000
4,194.0000
-3,818.0000
Total Unusual Items
279.0000
279.0000
662.0000
4,194.0000
-3,818.0000
Normalized EBITDA
-13,477.0000
-13,477.0000
-14,699.0000
-12,822.0000
-11,248.0000
12/31/2020 - 1/17/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

STXS Stereotaxis, Inc.
2.3000
-2.13%
 
HBIO Harvard Bioscience, Inc.
3.6200
+1.69%
 
UTMD Utah Medical Products, Inc.
65.92
-0.56%
 
ATR AptarGroup, Inc.
143.33
+2.25%
 
OCPNF Olympus Corporation
13.95
-1.13%
 
TRUMY Terumo Corporation
16.60
-0.12%
 
AVGR Avinger, Inc.
3.7301
-3.11%
 
SSMXY Sysmex Corporation
15.89
+0.25%
 
MBOT Microbot Medical Inc.
0.8800
+0.32%
 
NEPH Nephros, Inc.
2.1900
+2.34%